These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6444543)

  • 41. Selectivity of action of 5-FU: biochemical basis.
    Rustum YM; Danhauser L; Wang G
    Bull Cancer; 1979; 66(1):43-7. PubMed ID: 154352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
    Rustum YM; Danhauser L; Luccioni C; Au JL
    Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line.
    Sobrero AF; Moir RD; Bertino JR; Handschumacher RE
    Cancer Res; 1985 Jul; 45(7):3155-60. PubMed ID: 3159474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.
    Houghton JA; Houghton PJ; Wooten RS
    Cancer Res; 1979 Jul; 39(7 Pt 1):2406-13. PubMed ID: 156065
    [No Abstract]   [Full Text] [Related]  

  • 45. Differences in metabolism of 5-fluorouracil and 5-fluorouridine and regulation by glucosamine in human colon cancer multicell tumor spheroids.
    Chen TB; Bajzer Z; Macura S; Vuk-Pavlovic S
    NMR Biomed; 1999 May; 12(3):157-67. PubMed ID: 10414950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
    Patel M; Agarwal R; Ardalan B
    J Cancer Res Clin Oncol; 2004 Aug; 130(8):453-9. PubMed ID: 15205948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts.
    Houghton JA; Houghton PJ
    Cancer Treat Rep; 1982 May; 66(5):1201-6. PubMed ID: 7083222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
    Aschele C; Sobrero A; Faderan MA; Bertino JR
    Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
    Miwa M; Eda H; Fukuda H; Fujimoto K; Ishitsuka H
    Gan To Kagaku Ryoho; 1988 May; 15(5):1755-63. PubMed ID: 2967051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
    Spears CP; Gustavsson BG; Berne M; Frösing R; Bernstein L; Hayes AA
    Cancer Res; 1988 Oct; 48(20):5894-900. PubMed ID: 3167844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
    van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
    Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
    Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines.
    el Kouni MH; el Kouni MM; Naguib FN
    Cancer Res; 1993 Aug; 53(16):3687-93. PubMed ID: 8339277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man.
    Ardalan B; Macdonald J; Cooney D; Lippman M; Schein P
    Cancer Treat Rep; 1981; 65 Suppl 3():57-61. PubMed ID: 6213299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.
    Yin MB; Rustum YM
    Cancer Commun; 1991 Feb; 3(2):45-51. PubMed ID: 1825284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
    Wolberg WH; Morin J
    Cancer; 1981 Mar; 47(6):1313-7. PubMed ID: 7226054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
    Lönn U; Lönn S; Nylen U; Winblad G
    Cancer Res; 1989 Mar; 49(5):1085-9. PubMed ID: 2521812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of fluoropyrimidine metabolism by chlorpromazine.
    Tseng A; Brooks M; Cadman E
    Biochem Biophys Res Commun; 1986 Jul; 138(2):1009-14. PubMed ID: 3741420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.